Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 59.3141
- Book/Share 20.4356
- PB 34.301
- Debt/Equity 1.8705
- CurrentRatio 1.2777
- ROIC 0.2757
- MktCap 660674308850.0
- FreeCF/Share 2.0198
- PFCF 364.2889
- PE 45.4191
- Debt/Assets 0.3387
- DivYield 0.0083
- ROE 0.8836
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LLY | Daiwa Securities | Outperform | Neutral | -- | $700 | Aug. 18, 2025 |
| Downgrade | LLY | Leerink Partners | Outperform | Market Perform | -- | $715 | Aug. 7, 2025 |
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'
Published: August 19, 2025 by: Benzinga
Sentiment: Negative
Investors appear disappointed with Viking Therapeutics Inc.'s VKTX data from its Phase 2 trial of an obesity pill.
Read More
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks
Published: August 19, 2025 by: Benzinga
Sentiment: Negative
On Tuesday, Viking Therapeutics Inc. VKTX released the much-awaited data from its Phase 2 trial of VK2735 pill, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Read More
Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa
Published: August 18, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S's FDA approval for Wegovy in MASH and aggressive Ozempic pricing boost its position, despite recent stock declines and competitive pressure from Eli Lilly and Company. Both NVO and LLY face regulatory headwinds from U.S. drug pricing demands, but I believe much of the bad news is already priced in for both. Novo's strategic pricing, strong clinical data, and attractive valuation make it my preferred long-term pick, though both stocks offer upside from current levels.
Read More
2 Phenomenal Dividend Growth Stocks That Insiders Are Buying Hand Over Fist
Published: August 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points in This Article: Dividend growth investing offers stable income and capital appreciation through compounding returns.
Read More
Lilly Stock Down 5% This Month: Should You Buy the Dip?
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Negative
Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill orforglipron disappointed.
Read More
Eli Lilly: A Textbook Insider Buying Play
Published: August 18, 2025 by: Seeking Alpha
Sentiment: Positive
I initiate my coverage on Eli Lilly with a 'Buy' after an eventful Q2 earnings season. The stock looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and Mounjaro sales. LLY management is confident that the momentum in the weight loss segment will hold up. FY 2025 guidance was revised upwards for both the top and bottom lines.
Read More
Eli Lilly said it is in talks to raise drug prices in Europe, starting with weight-loss drug Mounjaro in the U.K., so it can meet President Trump's goal of bringing down prices in the U.S.
Published: August 14, 2025 by: WSJ
Sentiment: Negative
The move is part of the company's plan to renegotiate drug prices across other developed nations
Read More
Top Stock Movers Now: Tapestry, Deere, Eli Lilly, and More
Published: August 14, 2025 by: Investopedia
Sentiment: Negative
U.S. equities were lower at midday as wholesale inflation rose more than expected in July. The Dow Jones Industrial Average, S&P 500, and Nasdaq were all down.
Read More
3 Unusual Insider Transactions you Should Know About
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
While no single indicator can guarantee a stock's performance, the pattern of insider transactions can provide a powerful glimpse into a company's prospects.
Read More
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks?
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
Healthcare has been one of the toughest sectors for investors over the past year. In fact, over the last 12 months, it has been the worst performing sector in the entire market.
Read More
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
Published: August 12, 2025 by: Reuters
Sentiment: Negative
Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications.
Read More
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral obesity pill.
Read More
Lilly (LLY) Reliance on International Sales: What Investors Need to Know
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
Explore Lilly's (LLY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Read More
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
Calls of the Day: Eli Lilly, E.L.F. Beauty and CRH PLC
Published: August 08, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day and how to trade them.
Read More
Eli Lilly: 50% Upside For LLY Stock?
Published: August 08, 2025 by: Forbes
Sentiment: Positive
On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This positive performance was mainly fueled by the ongoing success of its medications, Mounjaro and Zepbound.
Read More
Eli Lilly's Experimental Weight-Loss Pill Data Disappoints
Published: August 07, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
A new, late-stage clinical study shows disappointing results for Eli Lilly's weight loss pill Orforglipron. The experimental drug has less success than its injectable counterparts like Zepbound, Wegovy, and Ozempic.
Read More
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
Published: August 07, 2025 by: Fast Company
Sentiment: Positive
It's been a week of wins for Eli Lilly's weight-loss drugs. In the company's second quarter earnings report on Thursday, it reported that sales of Mounjaro, its type-2 diabetes medication often used for weight loss, reached nearly $5.2 billion in revenue, up 68% from the same quarter last year and exceeding analyst estimates of $4.7 billion.
Read More
Leerink's Risinger on Eli Lilly downgrade: Triggered by disappointing obesity pill results
Published: August 07, 2025 by: CNBC Television
Sentiment: Negative
David Risinger, Leerink Partners senior research analyst, joins 'Power Lunch' to discuss how competitive Eli Lilly's business is, what to expect by the end of the decade and much more.
Read More
Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here's Why It's Down
Published: August 07, 2025 by: Forbes
Sentiment: Negative
Eli Lilly CEO David Ricks told CNBC the company was “not disappointed with these results,” which he noted were “right on thesis for us” despite falling “one or two points below what [Wall Street] had.” Orforglipron's average weight loss was “in the range” of what consumers would want to achieve, Ricks said.
Read More
LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Negative
LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.
Read More
Eli Lilly and Company (LLY) Q2 2025 Earnings Call Transcript
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Daniel M. Skovronsky - EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology David A.
Read More
Jobless Claims Increased More Than Expected
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
Another full morning of market data to go through today, which will help articulate where we are in several accounts of the massive U.S. economy. Pre-market futures were at peak highs just ahead of new economic prints this morning, but we remain in healthy, positive territory.
Read More
Top Stock Movers Now: DoorDash, Fortinet, Eli Lilly, and More
Published: August 07, 2025 by: Investopedia
Sentiment: Negative
U.S. equities were mixed at midday as the market continued to focus on earnings, and new U.S. tariffs kicked in. The Nasdaq was up, while the Dow Jones Industrial Average and S&P 500 fell.
Read More
Jobless Claims, Q2 Productivity, Q2 Earnings All Higher
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pre-market futures were at peak highs just ahead of new economic prints this morning, but we remain in healthy, positive territory.
Read More
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Lilly (LLY) Reports Q2 Earnings: What Key Metrics Have to Say
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Eli Lilly Weight-Loss Pill Trial Disappoints, Offsetting Solid Profit and Sales
Published: August 07, 2025 by: Investopedia
Sentiment: Negative
Ely Lilly (LLY) shares sank 14% Thursday when the pharmaceutical firm reported disappointing results from a late-stage study of its experimental obesity pill. The news offset Lilly's strong quarterly results.
Read More
Eli Lilly shares tumble on disappointing weight loss drug trial data
Published: August 07, 2025 by: Proactive Investors
Sentiment: Negative
Eli Lilly and Co (NYSE:LLY) shares fell more than 10% at the market open as disappointing late-stage trial data for the company's oral weight loss drug orforglipron drew focus from strong second quarter earnings and raised full-year guidance. The trial showed orforglipron users saw an average weight loss of 12.4% over 72 weeks, which was positive and met the primary endpoint.
Read More
"Disappointment Overall" for LLY Earnings, ABNB Shows Travel Weakness
Published: August 07, 2025 by: Schwab Network
Sentiment: Negative
Eli Lilly's (LLY) earnings beat wasn't enough draw investors in. The bigger focus was on the company's weight loss pill that showed "disappointing" results.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000